2 The study’s findings revealed PTP1B is a novel intracellular checkpoint and that PTP1B inhibition represses tumor growth and enhances the response of surface checkpoint inhibitors when used in ...

The study shows that by inhibiting the protein tyrosine phosphatase PTP1B in T cells, the body's immune response to cancer can be mobilized, helping to repress tumor growth. A collaborative study ...

MD-18 represents a breakthrough in targeting protein-tyrosine phosphatase 1B (PTP1B), a therapeutic target that has been shown to play a major role in glucose homeostasis and energy metabolism.